



Supplementary Figure 3. We categorized the subjects into the following three groups; patients with <20,000 IU/mL, 20,000–10,000,000 IU/mL, <10,000,000 IU/mL of HBV-DNA level. The cumulative probabilities of HCC development were not significantly different between these groups (overall $P=0.852$). HCC, hepatocellular carcinoma; AVT, antiviral therapy; FIB-4, fibrosis-4; IT, immune-tolerant; HBV, hepatitis B virus.